# R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

> **NCT04152577** · PHASE4 · UNKNOWN · sponsor: **Shandong Provincial Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** R2-combination chemotherapy
- **DRUG:** R-combination chemotherapy

## Key facts

- **NCT ID:** NCT04152577
- **Lead sponsor:** Shandong Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-05
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152577, "R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04152577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*